The blood-brain barrier blocks the entry of antibodies into the brain. This limits the potential use of antibody therapeutics to treat brain diseases, such as brain tumors. Elsewhere in the body, more ...
NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid ...
VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ...
The blood-brain barrier blocks the entry of antibodies into the brain. This limits the potential use of antibody therapeutics to treat brain diseases, such as brain tumors. Elsewhere in the body, more ...
ROCKVILLE, Md., Nov. 3, 2025 /PRNewswire/ -- Kaigene Inc., a U.S.-based biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, announced today that it has ...
Antibody therapeutics are a rapidly growing class of drugs used to treat infections as well as a range of diseases. Among them are cancer and autoimmunity particularly important, and the use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results